Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 41-45, January 1, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawabata, T. T.
Right arrow Articles by White, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawabata, T. T.
Right arrow Articles by White, K. L., Jr.

Enhancement of in Vivo and in Vitro Murine Immune Responses by the Cyclophosphamide Metabolite Acrolein1

Thomas T. Kawabata2 and Kimber L. White, Jr.

Departments of Pharmacology and Toxicology and Biostatistics, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0613

Cyclophosphamide (CY)-mediated immunoenhancement has been attributed to the inhibition of suppressor T-cell generation. In order to exert its effects on the immune system, metabolic activation of CY is required. The metabolite of CY responsible for its immunoenhancing properties are not known. Two reactive metabolites of CY which may inhibit suppressor T-cell generation are phosphoramide mustard and acrolein, compounds known to primarily bind to DNA and sulfhydryl groups, respectively. The objective of this study was to determine whether acrolein and/or phosphoramide mustard are capable of enhancing the immune response in a manner similar to CY. Administration of 100 µmol/kg of acrolein, i.v., to female C57BL/6 x C3H F1 mice 1 day before antigen exposure (sheep red blood cells) resulted in a 50% increase in the delayed-type hypersensitivity response (foot pad swelling). The Day 4 primary humoral immune response to sheep red blood cells was also increased by 88 and 60% after the administration of 30 and 100 µmol/kg acrolein 1 day before sensitization with sheep red blood cells. Exposure of splenocyte cultures to 3 x 10-7 and 10-6 M 4-hydroperoxy-CY or acrolein produced significant increases in the in vitro T-dependent antibody-forming cell response. In contrast, the antibody-forming cell response of cultures exposed to 3 x 10-8-10-4 M phosphoramide mustard did not increase above control levels. These results suggest that acrolein is responsible for the CY-induced enhancement of the immune response. Moreover, the enhancement may be produced by the binding of acrolein to sulfhydryl groups of molecules of cells required for the generation of suppressor T-cells.

1 Supported in part by USPHS Grants ES05317 and ES03434 and National Institute of Environmental Health Sciences Contract ES55094.

2 To whom requests for reprints should be addressed, at Box 613, Medical College of Virginia, Richmond, VA 23298-0613. Recipient of a National Research Service Award Postdoctoral Fellowship ES05317.

Received 6/23/87. Revised 9/23/87. Accepted 9/28/87.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.